tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

Astellas Pharma Reports Extraordinary Losses in Non-Consolidated Financial Results
Company AnnouncementsAstellas Pharma Reports Extraordinary Losses in Non-Consolidated Financial Results
3d ago
Astellas Pharma’s Earnings Call: Mixed Outcomes and Strategic Shifts
PremiumCompany Announcements
Astellas Pharma’s Earnings Call: Mixed Outcomes and Strategic Shifts
4d ago
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5d ago
Astellas Pharma Revises 2024 Financial Forecast Amid Core Business Growth and Impairment Losses
PremiumCompany Announcements
Astellas Pharma Revises 2024 Financial Forecast Amid Core Business Growth and Impairment Losses
14d ago
Astellas Pharma’s Resubmission for IZERVAY Accepted by FDA
PremiumCompany Announcements
Astellas Pharma’s Resubmission for IZERVAY Accepted by FDA
30d ago
Astellas Faces FDA Setback on IZERVAY Application
PremiumCompany AnnouncementsAstellas Faces FDA Setback on IZERVAY Application
3M ago
Astellas Pharma Faces Currency Losses in FY2024
Premium
Company Announcements
Astellas Pharma Faces Currency Losses in FY2024
3M ago
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
Astellas Pharma Withdraws EU Application for Key Drug
PremiumCompany Announcements
Astellas Pharma Withdraws EU Application for Key Drug
3M ago
Astellas Pharma’s VYLOY Gains FDA Approval for Cancer Treatment
PremiumCompany Announcements
Astellas Pharma’s VYLOY Gains FDA Approval for Cancer Treatment
4M ago
Astellas’ New Cancer Therapy Gains Japan Approval
PremiumCompany Announcements
Astellas’ New Cancer Therapy Gains Japan Approval
5M ago
Astellas Wins EU Approval for Advanced Cancer Drug
PremiumCompany Announcements
Astellas Wins EU Approval for Advanced Cancer Drug
5M ago
Bicycle says 45% of patients respond to bladder cancer drug, EN reports
PremiumThe FlyBicycle says 45% of patients respond to bladder cancer drug, EN reports
5M ago
MRK
PFE
Astellas Pharma Prices New Unsecured Bonds
Premium
Company Announcements
Astellas Pharma Prices New Unsecured Bonds
5M ago
Astellas Gains EC Approval for Advanced Urothelial Cancer Treatment
Premium
Company Announcements
Astellas Gains EC Approval for Advanced Urothelial Cancer Treatment
5M ago
New Urothelial Cancer Treatment Approved in China
PremiumCompany Announcements
New Urothelial Cancer Treatment Approved in China
6M ago
Astellas Pharma Records ¥5.5 Billion Charge
PremiumCompany Announcements
Astellas Pharma Records ¥5.5 Billion Charge
6M ago
ALPMF Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ALPMF Upcoming Earnings Report: What to Expect?
6M ago
Astellas Nears EU Approval for Groundbreaking Cancer Drug
PremiumCompany Announcements
Astellas Nears EU Approval for Groundbreaking Cancer Drug
6M ago
Astellas’ New Therapy Set to Transform Bladder Cancer Treatment
PremiumCompany AnnouncementsAstellas’ New Therapy Set to Transform Bladder Cancer Treatment
6M ago
Astellas Pharma Advances Governance and Diversity
Premium
Company Announcements
Astellas Pharma Advances Governance and Diversity
7M ago
Astellas’ XTANDI Wins Approval in China for Prostate Cancer
Premium
Company Announcements
Astellas’ XTANDI Wins Approval in China for Prostate Cancer
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >